New Insights from the TARGIT-A trial of radiotherapy during lumpectomy for breast cancer

14

12/1/2021

Invited talk at the Association of Breast Surgeons of India Conference, 26 Nov 2021

15

12/1/2021

TARGIT-IORT for breast cancer NCRI conference Nov 2021 - 5-Min Short talk

13

12/1/2021

Invited talk at the NHS Oncology Conference 23 Nov 2021

16

12/1/2021

The pro-screening lobby is locked into a mindset dating back to the late 1980s. Since then our understanding of the biology of breast cancer and its treatment has moved on whilst the screening programme continues without modification based on the results of trials reported in 1987. This lecture will discuss some of the harmful problems of this over-diagnosing system, and will look at the need for radical change to bring the entire programme up to date with modern practice based on risk assessment and risk management. Lunch Hour Lecture by Professor Michael Baum.

234

3/11/2021

The pro-screening lobby is locked into a mindset dating back to the late 1980s. Since then our understanding of the biology of breast cancer and its treatment has moved on whilst the screening programme continues without modification based on the results of trials reported in 1987. This lecture will discuss some of the harmful problems of this over-diagnosing system, and will look at the need for radical change to bring the entire programme up to date with modern practice based on risk assessment and risk management. This lecture marks Breast Cancer Awareness Month. Lunch Hour Lecture by Professor Michael Baum.

84

2/25/2021

Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT. Nathan J Coombs, Joel M Coombs, Uma J Vaidya, Julian Singer, Max Bulsara, Jeffrey S Tobias, Frederik Wenz, David J Joseph, Douglas A Brown, Richard Rainsbury, Tim Davidson, Douglas J A Adamson, Samuele Massarut, David Morgan, Ingrid Potyka, Tammy Corica, Mary Falzon, Norman Williams, Michael Baum, Jayant S Vaidya BMJ Open 2016;6:e010703. http://bmjopen.bmj.com/content/6/5/e010703.full http://blogs.bmj.com/bmjopen/2016/05/09/radiotherapy-during-surgery-could-save-millions-of-travel-miles-and-tonnes-of-co2/ The use of TARGIT intraoperative radiotherapy for eligible patients with breast cancer significantly reduces their journeys for treatment and has environmental benefits: 5 million miles of travel, 170 000 woman-hours and 1200 tonnes of CO2 (a forest of 100 hectares) per year in the UK

48

11/24/2018

Rethinking Neoadjuvant Chemotherapy for breast cancer- Prof Jayant Vaidya Original BMJ paper is available at https://www.bmj.com/content/360/bmj.j... Full paper is available at http://discovery.ucl.ac.uk/10041365/ Full paper + Discussion is available at http://bit.ly/nactbmj2018full The BMJ Podcast https://soundcloud.com/bmjpodcasts/ne... Key messages Neoadjuvant chemotherapy is being increasingly used for breast cancer despite higher rates of local recurrence and no evidence of survival benefit, mainly because of the immediate and dramatic pathological responses seen with newer drugs The increased pathological response of the primary tumour in the breast does not translate into a survival benefit even when given in the adjuvant setting, challenging the paradigm of “window of opportunity” studies We must acknowledge that neoadjuvant chemotherapy may not be beneficial to breast cancer patients We should consider reducing the widespread use of neoadjuvant chemotherapy

35

11/23/2018